Published in Virol J on March 29, 2006
Antisense transcription in the human cytomegalovirus transcriptome. J Virol (2007) 1.40
Function of human cytomegalovirus UL97 kinase in viral infection and its inhibition by maribavir. Rev Med Virol (2009) 1.31
Human cytomegalovirus UL28 and UL29 open reading frames encode a spliced mRNA and stimulate accumulation of immediate-early RNAs. J Virol (2009) 1.03
The search for new therapies for human cytomegalovirus infections. Virus Res (2010) 0.95
Resistance to maribavir is associated with the exclusion of pUL27 from nucleoli during human cytomegalovirus infection. Antiviral Res (2011) 0.84
Humanized mouse models of human cytomegalovirus infection. Curr Opin Virol (2015) 0.79
Antagonistic Relationship between Human Cytomegalovirus pUL27 and pUL97 Activities during Infection. J Virol (2015) 0.76
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother (2002) 2.98
A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency. J Virol (1999) 2.58
Gene content phylogeny of herpesviruses. Proc Natl Acad Sci U S A (2000) 2.24
Human cytomegalovirus resistance to antiviral drugs. Antimicrob Agents Chemother (2005) 1.83
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother (2003) 1.83
Phase I dose escalation trial evaluating the pharmacokinetics, anti-human cytomegalovirus (HCMV) activity, and safety of 1263W94 in human immunodeficiency virus-infected men with asymptomatic HCMV shedding. Antimicrob Agents Chemother (2002) 1.75
New strategies for prevention and therapy of cytomegalovirus infection and disease in solid-organ transplant recipients. Clin Microbiol Rev (2000) 1.75
Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol (2005) 1.51
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol (2003) 1.32
Mutations in the human cytomegalovirus UL27 gene that confer resistance to maribavir. J Virol (2004) 1.16
Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94. Clin Diagn Lab Immunol (2001) 1.09
Predictive efficacy of SCID-hu mouse models for treatment of human cytomegalovirus infections. Antivir Chem Chemother (2001) 1.02
Ganciclovir: an update of its use in the prevention of cytomegalovirus infection and disease in transplant recipients. Drugs (2001) 1.01
International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation (2010) 4.00
Potent and selective inhibition of human cytomegalovirus replication by 1263W94, a benzimidazole L-riboside with a unique mode of action. Antimicrob Agents Chemother (2002) 2.98
Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. J Virol (2003) 2.98
Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev (2010) 2.70
Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 2.45
Updated international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation (2013) 2.43
Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro. Antimicrob Agents Chemother (2002) 2.34
National Institutes of Health Consensus Development Conference Statement: management of hepatitis B. Ann Intern Med (2009) 2.19
Efficacy of delayed treatment with ST-246 given orally against systemic orthopoxvirus infections in mice. Antimicrob Agents Chemother (2006) 1.92
In vitro activities of benzimidazole D- and L-ribonucleosides against herpesviruses. Antimicrob Agents Chemother (2003) 1.83
Oral activity of a methylenecyclopropane analog, cyclopropavir, in animal models for cytomegalovirus infections. Antimicrob Agents Chemother (2004) 1.79
Extended spectrum of HIV-1 reverse transcriptase mutations in patients receiving multiple nucleoside analog inhibitors. AIDS (2003) 1.78
Synthesis and antiviral activity of (Z)- and (E)-2,2-[bis(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines: second-generation methylenecyclopropane analogues of nucleosides. J Med Chem (2004) 1.71
Comparative activities of lipid esters of cidofovir and cyclic cidofovir against replication of herpesviruses in vitro. Antimicrob Agents Chemother (2005) 1.60
Oral activity of ether lipid ester prodrugs of cidofovir against experimental human cytomegalovirus infection. J Infect Dis (2004) 1.55
Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice. Antimicrob Agents Chemother (2003) 1.53
Comparison of the antiviral activities of alkoxyalkyl and alkyl esters of cidofovir against human and murine cytomegalovirus replication in vitro. Antimicrob Agents Chemother (2005) 1.52
Human cytomegalovirus UL97 Kinase is required for the normal intranuclear distribution of pp65 and virion morphogenesis. J Virol (2005) 1.51
Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis (2004) 1.50
Human cytomegalovirus UL97 kinase activity is required for the hyperphosphorylation of retinoblastoma protein and inhibits the formation of nuclear aggresomes. J Virol (2008) 1.48
National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology (2009) 1.48
Oral treatment of murine cytomegalovirus infections with ether lipid esters of cidofovir. Antimicrob Agents Chemother (2004) 1.42
Synthesis and antiviral evaluation of alkoxyalkyl derivatives of 9-(S)-(3-hydroxy-2-phosphonomethoxypropyl)adenine against cytomegalovirus and orthopoxviruses. J Med Chem (2006) 1.39
Synergistic efficacy of the combination of ST-246 with CMX001 against orthopoxviruses. Antimicrob Agents Chemother (2007) 1.38
In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antiviral Res (2006) 1.38
Evaluation of nucleoside phosphonates and their analogs and prodrugs for inhibition of orthopoxvirus replication. Antimicrob Agents Chemother (2003) 1.37
Preclinical and toxicology studies of 1263W94, a potent and selective inhibitor of human cytomegalovirus replication. Antimicrob Agents Chemother (2002) 1.37
Activity and mechanism of action of N-methanocarbathymidine against herpesvirus and orthopoxvirus infections. Antimicrob Agents Chemother (2006) 1.37
Resistance of human cytomegalovirus to the benzimidazole L-ribonucleoside maribavir maps to UL27. J Virol (2003) 1.32
Inhibition of herpesvirus replication by a series of 4-oxo-dihydroquinolines with viral polymerase activity. Antiviral Res (2005) 1.31
Inhibitory activity of alkoxyalkyl and alkyl esters of cidofovir and cyclic cidofovir against orthopoxvirus replication in vitro. Antimicrob Agents Chemother (2004) 1.30
Viral and cell cycle-regulated kinases in cytomegalovirus-induced pseudomitosis and replication. PLoS Pathog (2007) 1.29
Multidrug resistance conferred by novel DNA polymerase mutations in human cytomegalovirus isolates. Antimicrob Agents Chemother (2006) 1.28
Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine. Clin Infect Dis (2003) 1.28
Artesunate as a potent antiviral agent in a patient with late drug-resistant cytomegalovirus infection after hematopoietic stem cell transplantation. Clin Infect Dis (2008) 1.23
How evolution of mutations conferring drug resistance affects viral dynamics and clinical outcomes of cytomegalovirus-infected hematopoietic cell transplant recipients. J Clin Microbiol (2005) 1.21
Interaction of the putative human cytomegalovirus portal protein pUL104 with the large terminase subunit pUL56 and its inhibition by benzimidazole-D-ribonucleosides. J Virol (2005) 1.20
Identification of the ATP-binding site in the terminase subunit pUL56 of human cytomegalovirus. Nucleic Acids Res (2003) 1.19
(Z)- and (E)-[2-Fluoro-2-(hydroxymethyl)cyclopropylidene]methylpurines and -pyrimidines, a new class of methylenecyclopropane analogues of nucleosides: synthesis and antiviral activity. J Med Chem (2004) 1.19
Stereoselective phosphorylation of cyclopropavir by pUL97 and competitive inhibition by maribavir. Antimicrob Agents Chemother (2010) 1.15
Efficacy of methylenecyclopropane analogs of nucleosides against herpesvirus replication in vitro. Nucleosides Nucleotides Nucleic Acids (2003) 1.14
N-(3,3a,4,4a,5,5a,6,6a-Octahydro-1,3-dioxo-4,6- ethenocycloprop[f]isoindol-2-(1H)-yl)carboxamides: Identification of novel orthopoxvirus egress inhibitors. J Med Chem (2007) 1.13
Analysis of the human cytomegalovirus genomic region from UL146 through UL147A reveals sequence hypervariability, genotypic stability, and overlapping transcripts. Virol J (2006) 1.13
Evaluation of AD472, a live attenuated recombinant herpes simplex virus type 2 vaccine in guinea pigs. Vaccine (2005) 1.12
Efficacy of CMX001 against herpes simplex virus infections in mice and correlations with drug distribution studies. J Infect Dis (2010) 1.12
Nucleotides and pronucleotides of 2,2-bis(hydroxymethyl)methylenecyclopropane analogues of purine nucleosides: synthesis and antiviral activity. J Med Chem (2005) 1.11
Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis (2003) 1.10
The biology of cytomegalovirus drug resistance. Curr Opin Infect Dis (2011) 1.10
Human cytomegalovirus uracil DNA glycosylase associates with ppUL44 and accelerates the accumulation of viral DNA. Virol J (2005) 1.09
A rapid DNA hybridization assay for the evaluation of antiviral compounds against Epstein-Barr virus. J Virol Methods (2007) 1.08
Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir. Antiviral Res (2004) 1.08
Maribavir sensitivity of cytomegalovirus isolates resistant to ganciclovir, cidofovir or foscarnet. J Clin Virol (2006) 1.08
Serine peptide phosphoester prodrugs of cyclic cidofovir: synthesis, transport, and antiviral activity. Mol Pharm (2008) 1.06
Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. J Virol (2012) 1.06
Synthesis of cyclopentenyl carbocyclic nucleosides as potential antiviral agents against orthopoxviruses and SARS. J Med Chem (2006) 1.06
A mechanistic paradigm for broad-spectrum antivirals that target virus-cell fusion. PLoS Pathog (2013) 1.05
Effects of substitutions of arginine residues on the basic surface of herpes simplex virus UL42 support a role for DNA binding in processive DNA synthesis. J Virol (2005) 1.05
Detection of cytomegalovirus drug resistance mutations by next-generation sequencing. J Clin Microbiol (2013) 1.04
Virucidal activity of polysaccharide extracts from four algal species against herpes simplex virus. Antiviral Res (2009) 1.04
Structure-activity relationships of (S,Z)-2-aminopurine methylenecyclopropane analogues of nucleosides. Variation of purine-6 substituents and activity against herpesviruses and hepatitis B virus. J Med Chem (2003) 1.04
The enantiomers of carbocyclic 5'-norguanosine: activity towards Epstein-Barr virus. Bioorg Med Chem (2002) 1.04
Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice. Antimicrob Agents Chemother (2007) 1.03
Interactions among antiviral drugs acting late in the replication cycle of human cytomegalovirus. Antiviral Res (2002) 1.03
Virologic characterization of multidrug-resistant cytomegalovirus infection in 2 transplant recipients treated with maribavir. J Infect Dis (2010) 1.01
Activities of benzimidazole D- and L-ribonucleosides in animal models of cytomegalovirus infections. Antimicrob Agents Chemother (2004) 1.00
Selective phosphorylation of antiviral drugs by vaccinia virus thymidine kinase. Antimicrob Agents Chemother (2007) 1.00
Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. Dig Dis Sci (2002) 0.99
Genetically engineered herpes simplex viruses that express IL-12 or GM-CSF as vaccine candidates. Vaccine (2005) 0.98
Identification of acetylated, tetrahalogenated benzimidazole D-ribonucleosides with enhanced activity against human cytomegalovirus. J Virol (2007) 0.98
Cyclopropavir inhibits the normal function of the human cytomegalovirus UL97 kinase. Antimicrob Agents Chemother (2011) 0.98
9-{[3-fluoro-2-(hydroxymethyl)cyclopropylidene]methyl}adenines and -guanines. Synthesis and antiviral activity of all stereoisomers1. J Med Chem (2006) 0.97
Mechanism of action of the ribopyranoside benzimidazole GW275175X against human cytomegalovirus. Antimicrob Agents Chemother (2004) 0.97
Resistance of human cytomegalovirus to D- and L-ribosyl benzimidazoles as a tool to identify potential targets for antiviral drugs. Nucleosides Nucleotides Nucleic Acids (2003) 0.97
Z-isomers of 2-hydroxymethylcyclopropylidenemethyl adenine (synadenol) and guanine (synguanol) are active against ganciclovir- and foscarnet-resistant human cytomegalovirus UL97 mutants. Antiviral Res (2002) 0.97
Determination of antiviral efficacy against lymphotropic herpesviruses utilizing flow cytometry. Antiviral Res (2003) 0.96
The 4',4'-difluoro analog of 5'-noraristeromycin: a new structural prototype for possible antiviral drug development toward orthopoxvirus and cytomegalovirus. Bioorg Med Chem (2005) 0.95
The search for new therapies for human cytomegalovirus infections. Virus Res (2010) 0.95
Combinatorial optimization of isatin-beta-thiosemicarbazones as anti-poxvirus agents. J Med Chem (2005) 0.95
Synthesis and biological activation of an ethylene glycol-linked amino acid conjugate of cyclic cidofovir. Bioorg Med Chem Lett (2006) 0.95
Inhibition of herpesvirus replication by 5-substituted 4'-thiopyrimidine nucleosides. Antimicrob Agents Chemother (2009) 0.95
Fluorinated methylenecyclopropane analogues of nucleosides. Synthesis and antiviral activity of (Z)- and (E)-9-{[(2-fluoromethyl-2-hydroxymethyl)-cyclopropylidene]methyl}adenine and -guanine. Bioorg Med Chem (2007) 0.94
Conserved retinoblastoma protein-binding motif in human cytomegalovirus UL97 kinase minimally impacts viral replication but affects susceptibility to maribavir. Virol J (2009) 0.94
Effect of immunization with herpes simplex virus type-1 (HSV-1) glycoprotein D (gD) plus the immune enhancer GPI-0100 on infection with HSV-1 or HSV-2. Vaccine (2005) 0.94
Phosphorylation of beta-D-ribosylbenzimidazoles is not required for activity against human cytomegalovirus. Antimicrob Agents Chemother (2002) 0.94